timothy sykes logo
INBS Stock Steadies As FDA Milestones And Revenue Growth Stack Up Thumbnail
G Google News

INBS Stock Steadies As FDA Milestones And Revenue Growth Stack Up

TIM SYKES•UPDATED SEP. 1, 2026, 12:32 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Intelligent Bio Solutions Inc. stocks have been trading up by 7.92 percent following upbeat sentiment from its latest product milestone.

Key Takeaways

  • Intelligent Bio Solutions completed the final multi-site Method Comparison Study for its fingerprint drug screening system, clearing a major data hurdle for its FDA 510(k) submission targeted for 2H 2026.
  • An FDA‑guided interference study is now complete, tightening the 510(k) package for codeine detection and supporting INBS’s push into the U.S. workplace drug screening market in H2 2026.
  • A key Usability Study showed non‑specialists can run the Intelligent Fingerprinting Drug Screening System, a bullish sign for broad workplace adoption if INBS wins U.S. clearance.
  • FY 2026 revenue climbed to $4.2M, up 38% year over year, with gross margin improving to 48.6%, though Intelligent Bio Solutions remains unprofitable and dependent on outside funding.
  • The business secured ISO 13485:2016 and ISO 9001:2015 recertification, aligning its UK operations with updated FDA quality rules and supporting INBS’s long‑term regulatory strategy.

Candlestick Chart

Live Update At 12:32:27 EDT: On Tuesday, September 01, 2026 Intelligent Bio Solutions Inc. stock [NASDAQ: INBS] is trending up by 7.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

INBS has been trading like a classic low‑float biotech‑style story stock, but with a real product and actual revenue behind it. Over the past few weeks, Intelligent Bio Solutions has walked up from sub‑$2 levels to close around $2.59, after printing highs near $3.49 in mid‑August. That spike and fade shows traders are already treating INBS as a catalyst‑driven momentum name.

Daily candles tell the story: a sharp run from about $1.96 on 2026/08/10 to above $3.30 on 2026/08/18, then a pullback that’s now stabilizing in the mid‑$2s. Intraday, the latest session shows a morning push to $2.84 followed by grinding consolidation between roughly $2.50 and $2.60. That’s typical price action when day traders test a breakout, then hand the ticker back to swing traders.

More Breaking News

Fundamentally, Intelligent Bio Solutions posted FY 2026 revenue of about $4.2M, with revenue growing 38% and gross margin improving to 48.6%. INBS is still losing money, with negative earnings and free cash flow of roughly -$3.2M in the latest quarter, but the price‑to‑sales ratio near 1.7 and price‑to‑book around 1.3 keep valuation in small‑cap territory where news can swing the chart fast.

Why Traders Are Watching INBS Now

Traders are glued to INBS because the company is lining up one regulatory domino after another. Intelligent Bio Solutions has completed the key multi‑site Method Comparison Study for its fingerprint‑based drug screening system, finishing all clinical data collection it needs for its FDA 510(k) program to detect codeine. For a tiny name like INBS, that’s a major de‑risking step on the road to U.S. clearance.

On top of that, INBS wrapped up an FDA‑guided interference study, another core technical plank in the 510(k) file. When a small diagnostics company can say it followed the agency’s playbook and checked off specific interference tests, traders listen. It tells the market that Intelligent Bio Solutions isn’t winging it; it’s tracking to a defined regulatory roadmap aimed at a 2H 2026 submission.

Then there’s the usability angle. A dedicated Usability Study showed non‑specialist operators can run the Intelligent Fingerprinting Drug Screening System effectively. For workplace drug testing, ease of use is everything. If office staff or site managers can handle INBS’s readers and consumable cartridges without a lab background, that widens the potential customer base across the U.S. market.

Layer on ISO 13485:2016 and ISO 9001:2015 recertification for the Intelligent Fingerprinting Drug Screening business, and you get a picture of Intelligent Bio Solutions tightening quality systems ahead of FDA review. Traders watching INBS see a company building the regulatory and operational scaffolding for a planned entry into the multi‑billion‑dollar U.S. workplace drug testing space in H2 2026. The recent Form 8‑K filing, even without public detail in the summary, only adds to the sense that more catalysts may be in the pipeline.

Conclusion

For active traders, INBS sits at the intersection of story and numbers. The story is clear: Intelligent Bio Solutions is pushing a fingerprint‑based drug screening platform toward FDA 510(k) submission in the second half of 2026, with multiple completed studies — method comparison, interference, and usability — already in the bag. Quality recertifications and alignment with updated FDA Quality Management System rules reinforce the thesis that INBS is serious about U.S. market entry.

The numbers show a company still in the build‑out phase. Revenue of $4.2M and 38% growth are solid for a micro‑cap, and a 48.6% gross margin hints at attractive unit economics from the expanding reader base and higher‑margin consumable cartridges. But Intelligent Bio Solutions remains loss‑making, burning cash and relying on external financing. That funding risk is exactly what short‑term traders in INBS need to track, especially around any future offerings or balance‑sheet moves.

This is where discipline matters. As Tim Sykes likes to say, “Trade the catalyst, not the story — and always, always cut losses quickly.” As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”. For INBS, that means respecting the volatility around each new FDA or corporate update, using the chart and liquidity as your guide, and treating every move as a trading setup, not a promise. This coverage is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”